Tuberous sclerosis cost-effectiveness of therapy: Difference between revisions
Created page with "__NOTOC__ {{Tuberous sclerosis}} {{CMG}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==Referenc..." |
Jose Loyola (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== Overview == | |||
A study from 2016 showed that for children with TSC presenting with refractory epilepsy (defined by the persistence of seizures despite the use of 2 anti-seizure drugs), the most cost-effective measure berween resective epilepsy surgery, vagus nerve stimulator implantation, ketogenic diet, and addition of a third anti-seizure drug, was the addition of a third drug into the medication regimen,<ref>Fallah, Aria, et al. "Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis complex." ''Epilepsy & Behavior'' 63 (2016): 79-88.</ref> | |||
==References== | ==References== | ||
Revision as of 23:55, 19 June 2020
|
Tuberous sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberous sclerosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Tuberous sclerosis cost-effectiveness of therapy |
|
Tuberous sclerosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Tuberous sclerosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
A study from 2016 showed that for children with TSC presenting with refractory epilepsy (defined by the persistence of seizures despite the use of 2 anti-seizure drugs), the most cost-effective measure berween resective epilepsy surgery, vagus nerve stimulator implantation, ketogenic diet, and addition of a third anti-seizure drug, was the addition of a third drug into the medication regimen,[1]
References
- ↑ Fallah, Aria, et al. "Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis complex." Epilepsy & Behavior 63 (2016): 79-88.